CN116635028A - c-MYC mRNA翻译调节剂及其在治疗癌症中的用途 - Google Patents

c-MYC mRNA翻译调节剂及其在治疗癌症中的用途 Download PDF

Info

Publication number
CN116635028A
CN116635028A CN202280009131.9A CN202280009131A CN116635028A CN 116635028 A CN116635028 A CN 116635028A CN 202280009131 A CN202280009131 A CN 202280009131A CN 116635028 A CN116635028 A CN 116635028A
Authority
CN
China
Prior art keywords
substituted
unsubstituted
branched
straight
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280009131.9A
Other languages
English (en)
Chinese (zh)
Inventor
大卫·威廉·谢泼德
詹森·保罗·蒂尔尼
阿维亚德·曼达比
艾里斯·阿尔罗伊
里纳·瓦色尔曼
王尧德
李海唐
尤尼·谢因伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enimo Biotech
Original Assignee
Enimo Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enimo Biotech filed Critical Enimo Biotech
Publication of CN116635028A publication Critical patent/CN116635028A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280009131.9A 2021-01-05 2022-01-05 c-MYC mRNA翻译调节剂及其在治疗癌症中的用途 Pending CN116635028A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL279972 2021-01-05
IL279972A IL279972A (en) 2021-01-05 2021-01-05 Substances that function as modulators of cmyc-mrna translation and their uses in cancer treatment
PCT/US2022/011203 WO2022150316A1 (en) 2021-01-05 2022-01-05 C-myc mrna translation modulators and uses thereof in the treatment of cancer

Publications (1)

Publication Number Publication Date
CN116635028A true CN116635028A (zh) 2023-08-22

Family

ID=82358087

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280009131.9A Pending CN116635028A (zh) 2021-01-05 2022-01-05 c-MYC mRNA翻译调节剂及其在治疗癌症中的用途

Country Status (8)

Country Link
US (1) US20220370431A1 (https=)
EP (1) EP4274569A4 (https=)
JP (1) JP2024502106A (https=)
CN (1) CN116635028A (https=)
AU (1) AU2022205591A1 (https=)
CA (1) CA3199333A1 (https=)
IL (2) IL279972A (https=)
WO (1) WO2022150316A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024010761A1 (en) * 2022-07-03 2024-01-11 Anima Biotech Inc. C-myc mrna translation modulators and uses thereof in the treatment of cancer
US12404283B2 (en) 2022-07-03 2025-09-02 Anima Biotech Inc. c-MYC mRNA translation modulators and uses thereof in the treatment of cancer

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3030982A1 (de) * 1979-08-21 1981-03-12 Yamanouchi Pharmaceutical Co., Ltd., Tokyo 2-phenylimidazo(2,1-b)benzothiazolderivate
US4464384A (en) * 1981-12-23 1984-08-07 Yamanouchi Pharmaceutical Co., Ltd. 2-Phenylimidazo[2,1-b]benzothiazole compounds, salts thereof, process of producing them, and pharmaceutical compositions containing them
WO2007109120A2 (en) * 2006-03-17 2007-09-27 Ambit Biosciences Corporation Imidazolothiazole compounds for the treatment of disease
CN101528743A (zh) * 2006-07-14 2009-09-09 安姆根有限公司 稠合杂环衍生物及使用方法
WO2019049061A1 (en) * 2017-09-07 2019-03-14 Glaxosmithkline Intellectual Property Development Limited 5- (1H-BENZO [D] IMIDAZO-2-YL) -PYRIDIN-2-AMINE AND 5- (3H-IMIDAZO [4,5-B] PYRIDIN-6-YL) -PYRIDIN-2- DERIVATIVES AMINE AS HISTONE ACETYLTRANSFERASE INHIBITORS OF C-MYC AND P300 / CBP FOR THE TREATMENT OF CANCER
WO2020172258A1 (en) * 2019-02-19 2020-08-27 Nalo Therapeutics Modulators of myc family proto-oncogene protein

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998006724A1 (en) * 1996-08-09 1998-02-19 Yamanouchi Pharmaceutical Co., Ltd. Metabotropic glutamate receptor agonists
CA2973739A1 (en) * 2015-02-03 2016-03-24 Active Biotech Ab Imidazo[2,1-b]thiazole and 5,6-dihydroimidazo[2,1-b]thiazole derivatives useful as s100-inhibitors
JP7360106B2 (ja) * 2017-12-28 2023-10-12 小胞体ストレス研究所株式会社 ベンゾチアゾイミダゾリル化合物を含有する小胞体ストレス調節剤

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3030982A1 (de) * 1979-08-21 1981-03-12 Yamanouchi Pharmaceutical Co., Ltd., Tokyo 2-phenylimidazo(2,1-b)benzothiazolderivate
US4464384A (en) * 1981-12-23 1984-08-07 Yamanouchi Pharmaceutical Co., Ltd. 2-Phenylimidazo[2,1-b]benzothiazole compounds, salts thereof, process of producing them, and pharmaceutical compositions containing them
WO2007109120A2 (en) * 2006-03-17 2007-09-27 Ambit Biosciences Corporation Imidazolothiazole compounds for the treatment of disease
CN101528743A (zh) * 2006-07-14 2009-09-09 安姆根有限公司 稠合杂环衍生物及使用方法
WO2019049061A1 (en) * 2017-09-07 2019-03-14 Glaxosmithkline Intellectual Property Development Limited 5- (1H-BENZO [D] IMIDAZO-2-YL) -PYRIDIN-2-AMINE AND 5- (3H-IMIDAZO [4,5-B] PYRIDIN-6-YL) -PYRIDIN-2- DERIVATIVES AMINE AS HISTONE ACETYLTRANSFERASE INHIBITORS OF C-MYC AND P300 / CBP FOR THE TREATMENT OF CANCER
WO2020172258A1 (en) * 2019-02-19 2020-08-27 Nalo Therapeutics Modulators of myc family proto-oncogene protein

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ARUN KAPOOR等: "Validation and Characterization of Five Distinct Novel Inhibitors of Human Cytomegalovirus", JOURNAL OF MEDICINAL CHEMISTRY, 19 March 2020 (2020-03-19), pages 3896 - 3907 *
CARLY M. SAYERS等: "Identification and Characterization of a Potent Activator of p53-Independent Cellular Senescence via a Small-Molecule Screen for Modifiers of the Integrated Stress Responses", MOLECULAR PHARMACOLOGY, vol. 5, no. 3, 10 December 2012 (2012-12-10), pages 594 - 604 *
HUI CHEN等: "Targeting oncogenic Myc as a strategy for cancer treatment", SIGNAL TRANSDUCTION AND TARGETED THERAPY, vol. 3, no. 1, 23 February 2018 (2018-02-23), pages 1 - 7 *
MATTHEW D. LLOYD: "High-Throughput Screening for the Discovery of Enzyme Inhibitors", JOURNAL OF MEDICINAL CHEMISTRY, 20 May 2020 (2020-05-20), pages 10742 *
STN REGISTRY: "CAS号：1053159-35-5", REGISTRY, 26 September 2008 (2008-09-26), pages 1 - 5 *

Also Published As

Publication number Publication date
IL279972A (en) 2022-08-01
IL303320A (en) 2023-07-01
EP4274569A1 (en) 2023-11-15
JP2024502106A (ja) 2024-01-17
EP4274569A4 (en) 2024-12-04
AU2022205591A9 (en) 2024-02-08
CA3199333A1 (en) 2022-07-14
AU2022205591A1 (en) 2023-07-06
US20220370431A1 (en) 2022-11-24
WO2022150316A1 (en) 2022-07-14

Similar Documents

Publication Publication Date Title
CN109310690B (zh) 异喹啉-3-基甲酰胺类及其制备和其用途
KR102429419B1 (ko) Rho-키나아제 억제제로서 티로신 아마이드 유도체
CN114401964B (zh) 一类具有brd4抑制活性的化合物、其制备方法及用途
JP2019509978A (ja) Ｒｏｃｋ阻害剤としてのスピロヘプタンサリチルアミドおよび関連性化合物
TW202309039A (zh) 用於靶向布魯頓氏酪胺酸激酶降解之化合物
TW202346288A (zh) 用於抑制ｋｉｆ１８ａ之化合物
CA2941984A1 (en) Pyridazine compound
JP2023529884A (ja) コラーゲン１翻訳阻害剤及びその使用方法
CN116635028A (zh) c-MYC mRNA翻译调节剂及其在治疗癌症中的用途
TW202440091A (zh) Ｎａｍｐｔ調節劑
EP4463452B1 (en) C-myc mrna translation modulators and uses thereof in the treatment of cancer
US12404283B2 (en) c-MYC mRNA translation modulators and uses thereof in the treatment of cancer
JP2025521719A (ja) ｃ－ＭＹＣ ｍＲＮＡ翻訳調節因子及び癌治療におけるその使用
US20250353862A1 (en) C-myc mrna translation modulators and uses thereof in the treatment of cancer
CN121464131A (zh) Mllt1和mllt3抑制剂化合物
TW202606657A (zh) 新型異雙功能蛋白質降解劑以及包含其的藥物組成物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination